Aripiprazole Solution
Product Images NDC 54838-570

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 54838-570). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Lannett Company, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (Aripiprazole Oral Solution 1)

Chemical structure of Aripiprazole, showing its molecular arrangement with chlorine atoms, nitrogen atoms, and multiple ring structures as part of the molecule.*

FDA Label Image

Carton (Aripiprazole Oral Solution 10)

Label for Aripiprazole Oral Solution 1 mg/mL in a 150 mL bottle, distributed by Lannett Company, Inc. The label includes storage instructions, a note to pharmacists to dispense the enclosed medication guide, and warnings about the shrink band seal. The product is an oral aqueous solution containing 1 mg of aripiprazole per mL.*

FDA Label Image

Bottle Label (Aripiprazole Oral Solution 11)

Label for Aripiprazole Oral Solution 1 mg/mL by Lannett Company, Inc. The 150 mL bottle label includes NDC 54838-570-59, storage instructions, and a barcode. The label states it is prescription only and includes tamper-evident seal warnings.*

FDA Label Image

Figure 1 (Aripiprazole Oral Solution 2)

A forest plot chart showing the effects of various other drugs on the pharmacokinetics of aripiprazole. The x-axis represents fold change relative to a reference without interacting drugs, ranging roughly from 0.5 to 3.0. The y-axis lists interacting drugs grouped by categories including CYP3A4 inhibitors and inducers, gastric acid blockers, and others, with pharmacokinetic metrics AUC and Cmax noted. Data points show fold changes and 90% confidence intervals for aripiprazole pharmacokinetics when co-administered with these drugs.*

FDA Label Image

Figure 2 (Aripiprazole Oral Solution 3)

A chart titled 'The effects of other drugs on dehydro-aripiprazole pharmacokinetics' showing fold changes with 90% confidence intervals in AUC and Cmax of dehydro-aripiprazole when co-administered with various drugs, including CYP3A4 and CYP2D6 inhibitors and inducers, gastric acid blockers, and others such as valproate and lithium. The x-axis represents change relative to reference without interacting drug.*

FDA Label Image

Figure 3 (Aripiprazole Oral Solution 4)

A figure illustrating the effects of Aripiprazole on the pharmacokinetics of various other drugs. It presents a horizontal bar chart showing fold changes and 90% confidence intervals in pharmacokinetic parameters such as AUC, Cmax, DM/DRP, and INR for drugs including dextromethorphan, warfarin (S- and R-), omeprazole, lamotrigine, valproate, lithium, lorazepam, venlafaxine, and escitalopram, relative to reference values without Aripiprazole interaction.*

FDA Label Image

Figure 4 (Aripiprazole Oral Solution 5)

A pharmacokinetic chart showing the effects of intrinsic factors on aripiprazole. The graph plots aripiprazole fold change with 90% confidence intervals for different special populations, including CYP2D6 metabolizer status, gender, age groups, hepatic impairment levels, and severe renal impairment, comparing AUC and Cmax changes relative to reference values.*

FDA Label Image

Figure 5 (Aripiprazole Oral Solution 6)

A pharmacokinetic chart displaying fold change and 90% confidence intervals for dehydro-aripiprazole under various conditions including CYP2D6 metabolizer status, gender, age groups, hepatic impairment severity, and severe renal impairment. The x-axis represents change relative to reference, ranging from 0.5 to 3.0, with comparisons of AUC and Cmax values shown as scatter points with error bars.*

FDA Label Image

Figure 6 (Aripiprazole Oral Solution 7)

A Kaplan-Meier curve chart showing the cumulative proportion of patients with relapse over time in a schizophrenia study comparing Aripiprazole and placebo. The x-axis represents days from randomization, and the y-axis shows the proportion with relapse. Two curves display relapse rates, with Aripiprazole having a lower proportion than placebo. The number of subjects at risk is tabulated below the x-axis for both groups.*

FDA Label Image

Figure 7 (Aripiprazole Oral Solution 8)

A Kaplan-Meier curve chart estimating the cumulative proportion of patients with relapse over days from randomization in a bipolar study. The chart compares relapse proportions between Aripiprazole and placebo groups, showing lines and a table of subjects at risk over time.*

FDA Label Image

Figure 8 (Aripiprazole Oral Solution 9)

Kaplan-Meier plot showing the cumulative proportion of patients experiencing relapse to any mood event over days from randomization in a bipolar study. The graph compares Aripiprazole versus placebo groups, with lines indicating the proportion with relapse on the vertical axis and days from randomization on the horizontal axis. A table below lists the number of subjects at risk for each group at various day intervals.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.